NIH Replication Prize recognises Technische Universität Braunschweig expertise powering NutriEV research
International recognition for Professor Michael Hust and Technische Universität Braunschweig highlights how recombinant antibodies can strengthen the reliability of extracellular vesicle research and accelerate innovation in precision nutrition.
Reproducibility is the foundation of scientific progress. Every discovery must be reliable enough for other researchers to repeat and confirm before it can become the basis for new diagnostics, therapies or technologies. This challenge is particularly important in life sciences, where experimental results often depend on the quality and consistency of the biological reagents used.
This commitment to scientific rigour has now received international recognition. Professor Michael Hust and Professor Stefan Dübel from Technische Universität Braunschweig (TU Braunschweig), together with an international consortium of researchers, have been awarded the National Institutes of Health (NIH) Replication Prize in Track 2 – Replication Exemplars (Antibody team). The prize recognises innovative strategies that improve the reproducibility of biomedical research by integrating robust replication practices into everyday scientific work.
For the NutriEV project, this achievement is particularly significant. Professor Michael Hust leads TU Braunschweig’s contribution to the project, where his expertise in recombinant antibody engineering is helping to develop the molecular tools needed to study nutritional extracellular vesicles with greater precision.
Why reproducibility matters
Many biomedical experiments rely on polyclonal antibodies produced from animal serum. While these antibodies have supported research for decades, they present an important limitation: every animal produces a slightly different mixture of antibodies. As a result, experiments performed today may not be perfectly reproducible months or years later, even when following the same protocol.
Recombinant antibodies offer a solution to this challenge.
Produced entirely in vitro using genetic engineering, recombinant antibodies are sequence-defined and recognise a single, well-characterised molecular target (epitope). Because their genetic sequence is known, the same antibody can be reproduced consistently in any laboratory, at any time and in unlimited quantities, improving both reliability and transparency in biomedical research.
As Professor Michael Hust explains:
“The aim of the NIH Replication Prize is to make experiments more reproducible, which remains a major challenge in life sciences. Protocols and biological reagents are often key sources of variation. Recombinant antibodies provide a sequence-defined, reproducible solution because they typically recognise a specific epitope recognise one specific epitope.”
Supporting the next generation of extracellular vesicle research
Within NutriEV, recombinant antibodies are much more than laboratory reagents. They are essential tools that enable researchers to identify, detect and characterise nutritional extracellular vesicles (nutriEVs) with greater confidence.
The project investigates nutriEVs naturally present in plants and fermented foods to understand how they influence gut health, obesity and metabolic disorders, while exploring their potential as future therapeutic tools and non-invasive biosensors.
One of NutriEV’s key objectives is to develop reliable biochemical tools capable of detecting extracellular vesicle biomarkers and tracking their behaviour across biological systems. TU Braunschweig leads this work package by generating recombinant antibodies against extracellular vesicle surface proteins using advanced phage display technology, creating highly specific molecular tools for extracellular vesicle analysis.
Professor Hust highlights the direct connection between the NIH award and the NutriEV project:
“For NutriEV, the detection of extracellular vesicle biomarkers for research, diagnostics and purification becomes more reliable and reproducible when recombinant antibodies are used.”
Greater reproducibility means that researchers can compare results across laboratories with increased confidence, accelerating scientific discovery and laying stronger foundations for future clinical and industrial applications.
Strengthening European research excellence
The NIH Replication Prize recognises not only a technological innovation but also a broader commitment to improving the quality and credibility of biomedical research worldwide. The award-winning team demonstrated how recombinant antibodies can replace traditional animal-derived antibodies while delivering more reliable, scalable and reproducible scientific results.
For NutriEV, this international recognition reinforces the strength of its multidisciplinary consortium and highlights the importance of combining expertise from antibody engineering, extracellular vesicle biology, glycobiology, nutrition and clinical research to address one of today’s most pressing health challenges: obesity and metabolic disorders.
As the project advances, these robust molecular tools will help ensure that discoveries about nutritional extracellular vesicles are built on reliable, reproducible science, bringing the vision of precision nutrition one step closer to reality.